Brief: Madrigal Pharmaceuticals Inc - Announces Exclusive Global License For Aro-Pnpla3 From Arrowhead
05/05/2026 13:31
May 5 (Reuters) - Madrigal Pharmaceuticals Inc MDGL.O: MADRIGAL PHARMACEUTICALS INC - ANNOUNCES EXCLUSIVE GLOBAL LICENSE FOR ARO-PNPLA3 FROM ARROWHEAD MADRIGAL PHARMACEUTICALS INC - ARROWHEAD TO RECEIVE $25 MILLION UPFRONT, UP TO $975 MILLION IN MILESTONES, PLUS ROYALTIES Source text: ID:nGNX6LMsKG Further company coverage: MDGL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Madrigal Pharmaceuticals
See all newsBrief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)